DEF 14A: Progyny, Inc. Announces Details for 2024 Annual Stockholders Meeting

Progyny, Inc. has set its 2024 Annual Meeting of Stockholders for May 23, 2024, to address director elections, auditor ratification, executive compensation, and other business.

Summary

• Progyny, Inc. will hold its 2024 Annual Meeting of Stockholders virtually on May 23, 2024, at 3:00 p.m. Eastern Time.
• Stockholders of record as of April 3, 2024, are eligible to vote.
• The meeting will address the election of four Class II directors (Peter Anevski, Roger Holstein, Jeff Park, and David Schlanger), ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and an advisory vote on executive compensation.
• The board of directors recommends voting FOR all director nominees, FOR the ratification of Ernst & Young LLP, and FOR the approval of executive compensation.
• The proxy materials, including the notice of the Annual Meeting, the proxy statement, and the Annual Report on Form 10-K for the fiscal year ended December 31, 2023, are available online at www.edocumentview.com/PGNY.
• In 2023, Progyny achieved record revenue of $1.089 billion and added 96 new clients.
• The company is expected to serve 6.7 million covered lives in 2024.
• The company's Net Promoter Score (NPS) was +80 in 2023.
• The company's clinical outcomes remained superior to national averages.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting strong financial performance and growth. However, the low say-on-pay vote in 2023 introduces a note of caution.

Positives

• Progyny achieved record revenue of $1.089 billion in 2023.
• The company added 96 new clients and is expected to serve 6.7 million covered lives in 2024.
• The company's Net Promoter Score (NPS) was +80 in 2023.
• Clinical outcomes exceeded national averages by between 14% and 72%.
• The company improved employee retention by 10% versus prior year, while achieving 50% headcount growth versus prior year.
• The company developed menopause and pregnancy and postpartum product lines to expand into other key areas of women's healthcare.
• The company maintained top rated IR program for 3rd year in a row and attained an upgraded AA rating with MSCI.

Negatives

• In 2023, only 32.7% of stockholders voted in favor of the say-on-pay proposal.

Risks

• The division of the board of directors into three classes with staggered three-year terms may delay or prevent a change of management or a change in control of Progyny.
• The company's future success depends on attracting, motivating, and retaining highly qualified and productive executives.

Future Outlook

Progyny expects to serve 6.7 million covered lives in 2024 and continue to expand its services.

Industry Context

Progyny operates in the healthcare industry, specifically focusing on fertility, family building, and women's health benefits. The company competes with other providers of similar services and aims to differentiate itself through its comprehensive solution, high-quality network, and member support.

Comparison to Industry Standards

• Progyny's clinical outcomes with respect to single embryo transfer rates, pregnancy rate, miscarriage rate, live birth rate, and IVF multiples rate remained superior to national averages.
• The company's Net Promoter Score (NPS) of +80 is considered industry-leading.

Stakeholder Impact

• Stockholders are provided with the opportunity to vote on key company matters.
• Employees are guided by the company's mission to empower healthier, supported journeys.
• Members benefit from the company's solution to remove financial barriers and provide equitable access to high-quality care.

Next Steps

• Stockholders are encouraged to vote their shares in advance of the Annual Meeting.
• The board of directors will consider the outcome of the advisory vote on executive compensation when making future decisions.
• The company intends to perform stockholder outreach again in 2024 and in the future.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Ernst & Young, Corporate Governance, Progyny